Overview
Cancer diagnostics firm's Q4 revenue rose 11% yr/yr, driven by higher-value tests
Adjusted EPS for Q4 beat analyst expectations
Company successfully resolved RaDaR ST patent litigation
Outlook
NeoGenomics expects 2026 revenue between $793 mln and $801 mln
Company anticipates 2026 net loss between $63 mln and $50 mln
NeoGenomics sees modest MRD revenue contribution in 2026, substantial growth in 2027
Result Drivers
HIGHER VALUE TESTS - NeoGenomics attributed Q4 revenue growth to a shift towards higher-value tests, including NGS, and strategic reimbursement initiatives
NGS GROWTH - NGS grew 23% in Q4, significantly ahead of market growth, driven by innovation in the community channel
PATHLINE ACQUISITION - Revenue growth was supported by contributions from the Pathline acquisition, despite lower non-clinical revenue
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Adjusted EPS | Beat | $0.06 | $0.04 (13 Analysts) |
Q4 Adjusted Net Income | $8 mln | ||
Q4 Net Income | -$10 mln | ||
Q4 Adjusted EBITDA | $13 mln | ||
Q4 Gross Profit | $83 mln | ||
Q4 Operating Expenses | $97 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 7 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy"
Wall Street's median 12-month price target for Neogenomics Inc is $14.00, about 23% above its February 13 closing price of $11.38
The stock recently traded at 69 times the next 12-month earnings vs. a P/E of 63 three months ago
Press Release: ID:nBw3MNlc4a
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)